Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RIBOLARIS neoadjuvant and adjuvant ribociclib plus endocrine therapy in high-risk ER-positive/HER2-negative breast cancer
2021-002322-24Phase 2Active
- Sponsor
- SOLTI
- Start
- Nov 2021
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ribociclib and letrozole in breast cancer, sponsored by SOLTI. Primary endpoint: Distant metastasis-free survival. Started Nov 2021; status: active.
02
Drugs
ribociclibletrozole
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2021-002322-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-002322-24.